<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03485144</url>
  </required_header>
  <id_info>
    <org_study_id>CT-DV-21</org_study_id>
    <nct_id>NCT03485144</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan</brief_title>
  <official_title>A Phase II Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Immunogenicity and Safety of TetraVax-DV in Healthy Adults in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medigen Vaccine Biologics Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medigen Vaccine Biologics Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine the immunogenicity and safety of TV003(TetraVax-DV), a
      live attenuated tetravalent dengue vaccine candidate, in healthy human subjects in Taiwan
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of TetraVax-DV assessed by plaque reduction neutralization titer 50% (PRNT50)</measure>
    <time_frame>Up to Day 90 after vaccination</time_frame>
    <description>Determination of the serum PRNT50 to each virus type for each subject at study day 28, 56 and 90 post vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of TetraVax-DV assessed by response rates</measure>
    <time_frame>Up to Day 90 after vaccination</time_frame>
    <description>Determine monovalent, bivalent, trivalent, and tetravalent seropositivity and seroconversion rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of immunogenicity of TetraVax-DV assessed by PRNT50</measure>
    <time_frame>Up to Day 365 after vaccination</time_frame>
    <description>Assess the duration of the antibody response by measured serum PRNT50 to each virus type for each subject at study day 180 and day 365 post vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of viremia following vaccination</measure>
    <time_frame>Up to Day 15 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of viremia following vaccination</measure>
    <time_frame>Up to Day 15 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of viremia following vaccination</measure>
    <time_frame>Up to Day 15 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the number of vaccinees with recoverable dengue virus.</measure>
    <time_frame>Up to Day 15 after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of TetraVax-DV assessed by frequency of solicited local adverse reactions.</measure>
    <time_frame>Up to Day 7 after vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of TetraVax-DV assessed by frequency of solicited systemic and unsolicited adverse reactions.</measure>
    <time_frame>Up to Day 21 after vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety of TetraVax-DV assessed by occurrence of adverse events and serious adverse events.</measure>
    <time_frame>Up to Day 365 after vaccination.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>TV003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Live Attenuated Virus Vaccine-TetraVax-DV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for TV003</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TV003</intervention_name>
    <description>Live attenuated virus vaccine-TetraVax-DV</description>
    <arm_group_label>TV003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo for TV003</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo for TV003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female between 20 and 70 years of age

          -  Good general health as determined by physical examination, laboratory screening, and
             review of medical history

          -  Available for the duration of the study

          -  Willingness to sign the informed consent document

          -  Female of childbearing potential willing to use effective contraception for the
             duration of the trial

        Exclusion Criteria:

          -  Females currently pregnant, as determined by positive β- human choriogonadotropin
             (HCG) test, and/or breast-feeding.

          -  Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic,
             rheumatologic, autoimmune, or renal disease by history, physical examination, and/or
             laboratory studies

          -  Behavioral, cognitive, or psychiatric disease

          -  Below lower limit of normal for absolute neutrophil count

          -  Any significant alcohol or drug abuse in the past 12 months

          -  History of a severe allergic reaction or anaphylaxis

          -  Self-reported systemic hypersensitivity to any of the vaccine components

          -  Severe asthma

          -  Known HIV, Hepatitis B or hepatitis C

          -  Any known immunodeficiency syndrome

          -  Use of anticoagulant medications

          -  Receive chronic administration of immunosuppressant drugs within 6 months prior to the
             administration of the study vaccine

          -  Use of any investigational product within 30 days before study vaccination or at any
             time during the study

          -  Asplenia

          -  Receive administration of immunoglobulins and/or any blood products within 12 months
             preceding the administration of the study vaccine or at any time during the study

          -  Fever or suspected fever within 72 hours prior to vaccination or tympanic temperature
             greater than 38°C on the day of vaccination

          -  Receive administration of any licensed live attenuated vaccines within 30 days
             preceding the administration of the study vaccine and ending 30 days after

          -  Receive administration of any licensed inactivated vaccines within 14 days preceding
             the administration of the study vaccine and ending 14 days after

          -  Any other condition that in the opinion of the investigator would jeopardize the
             safety or rights of a subject participating in the trial or would render the subject
             unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szu-Min Hsieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng-Ju Tsai</last_name>
    <phone>+886-2-77450830</phone>
    <phone_ext>208</phone_ext>
    <email>mengju@medigenvac.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard Cheng</last_name>
    <phone>+886-2-77450830</phone>
    <phone_ext>601</phone_ext>
    <email>howardcheng@medigenvac.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szu-Min Hsieh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

